Tasimelteon for CRY1-Linked Delayed Sleep-Wake Phase Disorder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for delayed sleep wake phase disorder (DSWPD) are inadequate, particularly for individuals with specific genotypes associated with the CRY1 and PER1 genes, as they do not effectively address sleep parameters such as latency to persistent sleep, sleep efficiency, REM sleep duration, total sleep time, and wake after persistent sleep.
Innovation Solution
Tasimelteon, a melatonin receptor agonist, is administered to patients with genotypes linked to DSWPD, such as the rs184039278 CRY1 allele, to improve sleep parameters by phase advancing the circadian timing system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for DSWPD, then general sleep issues may be addressed, but sleep parameters (latency to persistent sleep, sleep efficiency, REM sleep duration, total sleep time, wake after persistent sleep) are not effectively improved in patients with specific CRY1 and PER1 genotypes
Solution Approach 1:
The patent applies local quality by tailoring the treatment to specific genotype subgroups. Tasimelteon is prescribed specifically to patients with certain CRY1 and PER1 genotypes who exhibit delayed sleep-wake phase, rather than using a uniform treatment approach. This genotype-specific targeting improves treatment reliability for the intended population while acknowledging limitations for other genotypes.
Solution Approach 2:
The patent utilizes parameter changes by identifying specific genetic parameters (CRY1 and PER1 genotypes) that predict treatment response. By changing the selection criterion from general clinical diagnosis to specific genetic markers, the treatment achieves improved efficacy for the targeted subgroup, resolving the contradiction between overall reliability and genotype-specific effectiveness.
2Reliability
If tasimelteon is administered to advance circadian timing, then sleep parameters improve in genotype-specific patients, but the treatment requires precise genotype identification and timing
Solution Approach 1:
The patent applies preliminary action by performing genotype identification and circadian rhythm assessment before initiating tasimelteon treatment. Patients undergo genetic testing for CRY1 and PER1 variants and DLMO measurement to determine eligibility and optimal dosing timing. This preliminary characterization ensures that only appropriate candidates receive treatment and reduces protocol complexity during the treatment phase.
Solution Approach 2:
The patent implements feedback by using baseline sleep parameters and genotype information to guide treatment decisions, then monitoring sleep improvements to confirm efficacy. The treatment protocol includes assessing whether patients achieve the intended sleep parameter improvements, allowing for verification that the complex genotype-specific approach is delivering reliable benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Tasimelteon significantly improves sleep parameters like latency to persistent sleep, sleep efficiency, REM sleep duration, and total sleep time in individuals with genotypes associated with DSWPD, including those with the rs184039278 CRY1 allele.
Implementation Method 1
Tasimelteon is a circadian regulator that acts as a melatonin receptor agonist with selective activity at Melatonin, Type 1 (MT 1) and Type 2 (MT 2), receptors
Data Source
Figure 1
Figure 2
AI summary
The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY1) genotype associated with a circadian rhythm sleep disorder (CRSD) such as Delayed Sleep Wake Phase Disorder (DSWPD).